

**Amendments to the Claims**

This listing of claims will replace all prior versions, and listings, of claims in the application.

**Listing of Claims**

1.-62. (Cancelled).

63. (Currently Amended) An isolated human antibody or other specific antigen-specific binding molecule which specifically binds to a polypeptide selected from the group consisting of:

- (a) SEQ ID NO:2; and
- (b) ~~a fragment of SEQ ID NO:2 including at least 10 contiguous amino acids of SEQ ID NO:2; and~~
- (e)
- (b) a variant of SEQ ID NO:2 comprising a mutation selected from the group consisting that includes one of:
  - (i) a conservative amino acid substitution in SEQ ID NO:2;
  - (ii) an insertion of from 1-5 amino acids in SEQ ID NO:2; and
  - (iii) a deletion of from 1-5 amino acids in SEQ ID NO:2;

wherein the polypeptide has chemotactic activity or activates neutrophils or monocytes.

64. (Previously Presented) The isolated human antibody of claim 63, wherein said antibody is a neutralizing antibody.

65. (Previously Presented) The isolated human antibody of claim 63, wherein said antibody is a polyclonal antibody.

66. (Previously Presented) The isolated human antibody of claim 63, wherein said antibody is a monoclonal antibody.

67. (Currently Amended) A composition comprising ~~an~~ the antibody or specific antigen-specific binding molecule of claim 63 and an acceptable excipient.

68. (Currently Amended) The composition of claim 67, wherein the antibody or specific antigen-specific binding molecule is labeled.

69. (Previously Presented) The composition of claim 67, wherein said label is selected from the group consisting of radionuclides, enzymes, substrates, cofactors, inhibitors, fluorescent agents, chemiluminescent agents and magnetic particles.

70. (Withdrawn) A method for treating inflammation or a disease of the adenoid comprising administering to a subject an effective amount of the composition of claim 67.

71. (Withdrawn) A method for treating tonsilitis, Epstein-Barr virus, Hodgkin's disease, neoplasms or nonspecific pharyngitis comprising administering to a subject an effective amount of the composition of claim 67.

72. (Previously Presented) The antibody of claim 66, wherein said antibody has an affinity of at least  $10^8 \text{ M}^{-1}$ .

73. (Previously Presented) The antibody of claim 72, wherein said antibody has an affinity of at least  $10^9 \text{ M}^{-1}$ .

74. (Previously Presented) The antibody of claim 73, wherein said antibody has an affinity of at least  $10^{10} \text{ M}^{-1}$ .

75. (Currently Amended) The isolated human antibody or other specific antigen-specific binding molecule of claim 63, wherein the polypeptide comprises SEQ ID NO:2.

76. (Currently Amended) The isolated human antibody or other specific antigen-specific binding molecule of claim 63, selected from the group consisting of:

- a) a single chain antibody;
- b) an Fab fragment; and
- c) an F(ab')2 fragment.

77. (Currently Amended) An isolated human antibody or other specific antigen-specific binding molecule which specifically binds to a polypeptide encoded by a polynucleotide selected from the group consisting of:

- (a) SEQ ID NO:1; and
- (b) a polynucleotide that hybridizes ~~under stringent conditions~~ to a complement polynucleotide sequence of SEQ ID NO:1 under stringent conditions comprising washing at 68°C in a solution of 0.2 × SSC and 0.1% SDS;

wherein the polypeptide has chemotactic activity or activates neutrophils or monocytes.